Rhythm Pharmaceuticals Reports Efficacy in New Obesity Drug Trial
Boston, Tuesday, 4 August 2026.
Preliminary Phase 2 data shows Rhythm Pharmaceuticals’ novel weekly injection achieved an 11.6% mean BMI reduction in 16 weeks, offering promising hope for hypothalamic obesity treatment.
Preliminary Trial Results Announced
On August 4, 2026, Rhythm Pharmaceuticals (NASDAQ: RYTM) announced preliminary Phase 2 trial data for its investigational drug RM-718 [1]. The Boston-based company reported a positive efficacy signal in treating acquired hypothalamic obesity [1]. Patients receiving the weekly MC4R agonist achieved an 11.6% mean reduction in body mass index (BMI) from baseline at 16 weeks [1]. This announcement coincides with the company’s scheduled conference call to discuss second-quarter 2026 financial results [1][3].
Clinical Efficacy and Safety Profile
This efficacy is consistent with existing therapies such as setmelanotide and bivamelagon [1]. In the open-label trial, 7 out of 11 enrolled patients achieved this reduction by Week 16 [1]. Regarding safety, the treatment was generally well-tolerated with common adverse events including injection site reactions, nausea, and vomiting [1]. Only two mild cases of hyperpigmentation were reported, isolated to the injection site [1]. The company previously received FDA approval for Imcivree for acquired hypothalamic obesity on March 19, 2026, expanding its market beyond rare genetic forms [3].
Market Context and Financial Position
As of August 2, 2026, Rhythm Pharmaceuticals stock traded at $99.25, within a 52-week range of $75.82 to $117.62 [2]. Analyst consensus includes 15 buy ratings and 1 hold rating, with an average target price of $138.80 [2]. This target represents a potential upside of 39.849 percent from the reported trading price [2]. Investors remain attentive to international rollout speeds and sales reporting segmentation following the recent approval [3].
Investment Outlook and Pipeline
The company continues to develop oral candidates like bivamelagon and RM-718 to extend its franchise beyond the 2034 patent expiry of Imcivree [3]. Rhythm Pharmaceuticals estimates existing cash and investments are sufficient to fund operations for at least 24 months from the article date [1]. Future data announcements are anticipated for ongoing clinical trials, including substudies for congenital hypothalamic obesity [1]. The firm maintains a growth trajectory, though investors are advised to weigh developmental stage financial risks against potential biotechnology rewards [2].